Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
174
resultados
Última actualización
17/09/2025 [07:45:00]
Resultados 50 a 75 de 174
Resumen de: WO2025152918A1
Provided in the present invention are humanized anti-human CD132 monoclonal antibodies and the use thereof. The present invention performs humanized transformation on the basis of monoclonal chimeras 2D4 and 5H10, so as to obtain high-affinity humanized monoclonal antibodies h2D4H4K12 and h5H10H6K4 targeting the human CD132 by means of screening; therefore, without attenuating the antibody activity, the immunogenicity of parental chimeras is reduced, thus reducing the possible risk that medicated patients may generate immune responses on the antibodies. The monoclonal antibodies can be used for prevention, neutralization or treatment of autoimmune diseases related to IL-4, IL-7, IL-9, IL-15 and/or IL-21 cytokines, e.g. systemic lupus erythematosus, rheumatoid arthritis, vitiligo, psoriasis, alopecia areata, inflammatory bowel disease, systemic sclerosis, graft-versus-host disease and aplastic anemia.
Resumen de: US2025237648A1
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.
Resumen de: WO2025155566A1
An MIS beveled driver and methods are provided for implanting beveled IBS bone compression and fully threaded screws to encourage bone fusion. The driver includes an elongated driver shaft extending from a shaped distal end to a proximal handle, a beveled sleeve having an angled distal-most surface adjacent to the shaped distal end that couples with the bone screw, and beveled marks on the driver shaft to indicate an orientation of the sleeve. The sleeve is affixed to the driver shaft such that the angle of the distal-most surface remains aligned with the beveled marks. The sleeve ensures that the bone screw only assembles with the driver in an orientation that enables aligning a proximal head portion of the bone screw to be flush with the surrounding bone surface. The sleeve includes a radio marker to enable observation of the bone screw by way of fluoroscopy.
Resumen de: US2025237665A1
A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohn's disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohn's disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: CN119546632A
The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.
Resumen de: CN120330323A
The invention discloses an intestinal flora marker related to a children inflammatory bowel disease, a product and application of the intestinal flora marker. The intestinal flora marker disclosed by the invention is one or more of streptococcus salivarius, bacteroides ovatus, bacteroides vulgaris, clostridium altaicum, actinomycetes decayed tooth and clostridium difficile, and can be applied to prediction and diagnosis of patients with the inflammatory bowel disease in children, the diagnosis process is completely noninvasive, and the accuracy is high.
Resumen de: CN120329225A
The invention relates to the technical field of biology, in particular to isoconic acid and analogues thereof, a preparation method of the isoconic acid and the analogues thereof and application of the isoconic acid and the analogues in diagnosis and treatment of inflammation-related diseases. The invention finds that isoconic acid as an inflammation biomarker and a novel metabolite with an anti-inflammatory effect has a relatively strong inhibition effect on M1 polarization of human and mouse macrophages induced by lipopolysaccharide (LPS); the LPS-induced mouse inflammation model has the effects of prolonging the survival time and relieving inflammation phenotypes of tissues such as brain, spleen and liver; the anti-inflammatory effects of expression, secretion and the like of inflammatory factors are reduced. The composition has the effects of reducing adipose tissue inflammatory factors and relieving weight gain in a high-fat diet inflammation model; in a mouse inflammatory bowel disease model, the compound has the effects of increasing the length and reducing steel research pathological scores and inflammatory factors. Therefore, the isoconic acid can be used for diagnosing and treating inflammatory diseases, such as septicopyemia, inflammatory bowel disease, neuroinflammation, inflammation caused by high fat diet and the like.
Resumen de: US2025230505A1
Disclosed herein are methods, kits and compositions for treating an inflammatory disease. These methods, kits and compositions may be particularly useful for subjects carrying a risk genotype and/or expressing a transcriptomic risk signature that is indicative of severe inflammatory disease phenotypes for which existing treatment options are limited.
Resumen de: CN120309604A
The invention discloses a diagnosis and treatment prodrug based on inflammatory disease activation and a preparation method and application thereof, and belongs to the technical field of biological medicine. The diagnosis and treatment prodrug disclosed by the invention not only can realize accurate diagnosis on an inflammatory part through NIR fluorescence imaging, but also can selectively release ozanimod in an inflammatory tissue to play a role in efficiently treating colitis, so that the toxicity to normal tissues is reduced. Diagnosis and treatment prodrug with structure as shown in general formula I: # imgabs0 #
Resumen de: CN120299684A
The invention discloses an intelligent diagnosis system and method for Crohn disease muscular layer change, and belongs to the technical field of medical image analysis and artificial intelligence, and the system comprises an image collection and processing module which is used for receiving an MRI image of a patient, carrying out the de-noising and enhanced comparison, providing high-quality image data for the subsequent scoring analysis, and carrying out the calculation of the image data based on a preset algorithm, automatically sketching a target area; the image feature extraction module is used for extracting 102 radiomics features from the T1 enhanced image by using a Pyradiomics tool, and combining DCE-MRI functional parameters and conventional magnetic resonance parameters; the clinical data integration module is used for integrating clinical indexes of patients and constructing a multi-dimensional feature pool; and the score calculation module is used for calculating the extracted features. According to the intelligent diagnosis system and method for the Crohn disease muscular layer change, scientific research development can be promoted, an innovative muscular layer change evaluation scheme provides reliable data support for further scientific research, and the research progress in the field can be promoted.
Resumen de: US2025223626A1
The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacterium, or hydrogen sulfide.
Resumen de: EP4582099A2
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
Resumen de: CN120267829A
The invention provides an application of a substance for up-regulating the expression level of at least one biomarker in a signal channel of a protease activated receptor 2 (PAR2)-mediated lysosome function in preparation of a composition for one or more of the following: (1) regulating lysosome acidification in a cell; (2) regulating the autophagy function in the cells; (3) regulating autophagosome-lysosome fusion in the cells; (4) the accumulation of reactive oxygen species (ROS) in cells is reduced; (5) reducing the DNA damage level in the cells; (6) reducing the expression level of inflammatory factors in cells; (7) improving or treating acute injury of colitis in the subject; (8) improving or treating the inflammatory bowel disease of the subject; (9) preventing, ameliorating or treating inflammatory cancer transformation in a subject; and (10) preventing, ameliorating or treating colorectal cancer in the subject; wherein the biomarker is selected from PAR2 (Protein Activated Receptor 2), FOXA2 (Forkhead Frame Protein A2) and a lysosome V-type proton pump subunit ATP6V0E1.
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: CN120254281A
The invention relates to application of an intestinal mucosa inflammation serum marker in preparation of a diagnosis and treatment product for treating the intestinal mucosa inflammation state of a patient suffering from Crohn disease and predicting the treatment effect of infliximab, and belongs to the technical field of biological medicine, and the intestinal mucosa inflammation serum marker is matrix remodeling related 5 protein (MXRA5). When the matrix remodeling related 5 protein (MXRA5) is used as a target spot for serum protein detection, high sensitivity and specificity are achieved, and therefore the MXRA5 protein can be used as a screening target spot for predicting the intestinal mucosa inflammation state of a patient suffering from the Crohn disease and the treatment effect of the infliximab.
Resumen de: CN120254292A
The invention provides a marker combination for predicting recurrence of ulcerative colitis and application thereof, and particularly, the marker is at least one of SLC6A14, MUC-2 and Nanncy index. The marker can be used for diagnosis and recurrence prediction of ulcerative colitis, and especially has relatively strong detection capability for relieving and recurrence conditions of patients after clinical drug treatment.
Resumen de: CN120249471A
The invention relates to the field of biological medicine, and particularly provides application of a membrane protein CMTM3 as a drug target for treating inflammatory bowel disease and related colorectal cancer. The invention discovers and verifies that deletion of Cmtm3 can protect mice from AOM/DSS induced colorectal cancer (CAC) for the first time. A further research result proves that the endothelial cell-derived CMTM3 promotes the development of enteritis. The Cmtm3 gene knockout and the imatinimex can regulate the vascular permeability in a targeted manner and have a considerable curative effect. The application also discloses that the CMTM3 promotes vascular permeability to aggravate enteritis by stabilizing CLTC and increasing gridding protein mediated endocytosis of VE-cadherin in endothelial cells, thereby promoting the development of inflammation-related colon cancer, which indicates that the CMTM3 can be used as a potential therapeutic target for enteritis and colon cancer (CAC).
Resumen de: CN120254102A
The invention provides a quality control method of an effective component of alhagi sparsifolia for treating ulcerative colitis and application of the quality control method, and the method comprises the following steps: characterizing the material composition of the effective component of alhagi sparsifolia by using an ultra-high performance liquid chromatography-mass spectrometry technology, and determining key active components by combining network pharmacology prediction and topological analysis; the quality internal control method for the effective components of the alhagi sparsifolia for treating the ulcerative colitis is constructed by adopting a high performance liquid chromatography technology and a thin-layer chromatography technology, the material information of the effective components of the alhagi sparsifolia can be comprehensively reflected, the quality of the effective components of the alhagi sparsifolia in different batches can be effectively monitored, and the method is high in precision, good in reproducibility and suitable for industrial production. The method can be used for controlling the quality of the effective components of the alhagi sparsifolia for treating ulcerative colitis, and provides a basis for solving the problem that the existing standard cannot comprehensively and systematically analyze the material composition and content control of the effective components of the alhagi sparsifolia.
Resumen de: US2025213709A1
The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.
Resumen de: WO2025141157A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (AI) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the AI is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC- features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: EP4578401A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (Al) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the Al is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC-features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
Resumen de: US2024075102A1
Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.
Resumen de: CN120210101A
The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.
Nº publicación: CN120214122A 27/06/2025
Solicitante:
SUZHOU DUSHUHU HOSPITAL DUSHU LAKE HOSPITAL AFFILIATED TO SUZHOU UNIV
\u82CF\u5DDE\u5E02\u72EC\u5885\u6E56\u533B\u9662\uFF08\u82CF\u5DDE\u5927\u5B66\u9644\u5C5E\u72EC\u5885\u6E56\u533B\u9662\uFF09
Resumen de: CN120214122A
The invention provides application of alpha-ZAL in screening the risk of Crohn disease, and belongs to the technical field of biochemical detection. According to the present invention, the endocrine disrupter alpha-zeenol is adopted as the marker for screening the risk of the Crohn disease, the high performance liquid chromatography-tandem mass spectrometry detection technology is adopted to detect the endocrine disrupter, and the endocrine disrupter is prepared into the kit for the risk analysis of the Crohn disease.
BOPI
Sede Electrónica
